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Background: The extracellular signal-regulated kinase (ERK) pathway regulates cell growth, and is hyper-acti-
vated and associated with drug resistance in hepatocellular carcinoma (HCC). Metabolic pathways are pro-
foundly dysregulated in HCC. Whether an altered metabolic state is linked to activated ERK pathway and
drug response in HCC is unaddressed.
Methods: We deprived HCC cells of glutamine to induce metabolic alterations and performed various assays,
including metabolomics (with 13C-glucose isotope tracing), microarray analysis, and cell proliferation assays.
Glutamine-deprived cells were also treated with kinase inhibitors (e.g. Sorafenib, Erlotinib, U0126 amongst
other MEK inhibitors). We performed bioinformatics analysis and stratification of HCC tumour microarrays
to determine upregulated ERK gene signatures in patients.
Findings: In a subset of HCC cells, the withdrawal of glutamine triggers a severe metabolic alteration and ERK
phosphorylation (pERK). This is accompanied by resistance to the anti-proliferative effect of kinase inhibitors,
despite pERK inhibition. High intracellular serine is a consistent feature of an altered metabolic state and con-
tributes to pERK induction and the kinase inhibitor resistance. Blocking the ERK pathway facilitates cell pro-
liferation by reprogramming metabolism, notably enhancing aerobic glycolysis. We have identified 24 highly
expressed ERK gene signatures that their combined expression strongly indicates a dysregulated metabolic
gene network in human HCC tissues.
Interpretation: A severely compromised metabolism lead to ERK pathway induction, and primes some HCC
cells to pro-survival phenotypes upon ERK pathway blockade. Our findings offer novel insights for under-
standing, predicting and overcoming drug resistance in liver cancer patients.
Fund: DFG, BMBF and Sino-German Cooperation Project
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Research in context
Evidence before this study
Compared to healthy liver tissues, major components of metab-
olism such as metabolites and enzymes are abnormally
expressed in liver cancer. It is also known that the RAS-RAF-
MEK-ERK signalling pathway is hyperactivated in this cancer
type, and that some inhibitors used in clinical cancer therapy
act by blocking the ERK pathway. Treatment options for liver
cancer are very limited, resistance to ERK pathway inhibitors is
a known challenge, and factors that cause resistance to treat-
ment are largely undefined. Whether liver cancer metabolic
alteration is linked to the ERK signalling activation and drug
response is unknown. In addition, whether the severity of met-
abolic alterations can predict tumours that will best respond to
treatment is unexplored.
Added value of this study
We have demonstrated in vitro that severe metabolic altera-
tions, ERK pathway activation, and the likelihood of drug
resistance are interconnected in a crosstalk in which the meta-
bolic derangement is ostensibly the initiating event. When
metabolism is impaired, the ERK pathway becomes activated.
Under this altered condition, treatment with ERK pathway
inhibitors facilitate proliferation by inducing an increased
metabolic activity, particularly glycolysis. We show that serine
also accumulates, and can at least partially contribute to the
pERK induction, although the mechanism is currently unclear.
Using gene expression profile of human liver cancer tissues,
we show that a high expression of ERK pathway components
strongly correlate with the metabolic gene alterations often
seen in liver tumour samples. We also presented 24 ERK gene
signatures that could serve as a useful panel for predicting
ERK pathway activation and the severity of HCC tumour meta-
bolic changes.
Implications of all the available evidence
This study highlights the possibility that the inhibitors of ERK
pathway induce contradictory effects in liver cancer, despite
suppressing the pathway. Specifically, when liver cancer
metabolism is fairly ‘normal’ or ‘intact’ (e.g. at the early stage of
the disease) these inhibitors could be effective in preventing
tumour progression. However, even though these inhibitors
remain effective in blocking ERK pathway, when metabolism is
severely compromised (e.g. at the advanced disease stage), the
inhibitors can induce an undesired increase in metabolism,
which favours tumourigenic activities. Therefore, tumour meta-
bolic state at treatment and the specific effect of a treatment on
tumour metabolism  even for compounds not designed to tar-
get metabolic pathways  may be an important factor to con-
sider in future HCC treatment endeavours. Similarly, the
combination of ERK pathway inhibitors with inhibitors of
metabolism is an important research direction to be explored.
Insights from this study also provide a rationale for exploring
ways to include tumour metabolic features in the prediction of
patients best suited for therapies that block the ERK pathway.
Further studies are required to better explore metabolism-ERK
signalling crosstalk in improving HCC patients’ response to
treatment.
2 Z.C. Nwosu et al. / EBioMedicine 54 (2020) 102699aKG alpha ketoglutarate
EGF epidermal growth factor
ERK extracellular signal-regulated kinase
GSEA gene set enrichment analysis
HCC hepatocellular carcinoma
MAPK mitogen-activated protein kinase
MTT 3-(4,5-dimethylthiazol-2-yl)2,5-diphenyltetrazo-
lium bromide
RT-qPCR reverse transcription quantitative polymerase chain
reaction
SBP serine biosynthesis pathway
TCA tricarboxylic acid1. Introduction
Epidemiological studies report a rising incidence of liver cancer and
low patient survival rates [1,2]. There is an urgent need for effective ther-
apies against liver cancer, of which >80% of cases are hepatocellular car-
cinoma (HCC). Kinase inhibitors (e.g. Sorafenib and Erlotinib) have been
explored in the clinic for HCC therapy based on promising anti-cancer
efficacy in preclinical studies. The majority of these inhibitors act by
blocking the mitogen-activated protein kinase/extracellular signal-regu-
lated kinase pathway (ERK pathway). This pathway is widely known to
be upregulated in various cancer types and is considered a central driver
of tumour progression. However, many patients who initially respond to
therapies targeting the ERK pathway later develop drug resistance [3-5].
To date, the only first-line therapy against advanced HCC is the multi-
kinase inhibitor Sorafenib, which extends survival by »3 months. Simi-
larly, Regorafenib, whichwas recently approved as a second-line therapy
for patients whose tumour resisted Sorafenib also extends survival by
»3 months [6]. Clinical trials to improve the survival benefits of Sorafe-
nib have been largely unsuccessful [7,8]. It is therefore important to
understand the factors that contribute to poor response to therapy in
order to better predict which patients will benefit from targeted
therapies.
Metabolic alterations promote cancer cell survival and progression
[9,10]. Human liver cancer harbours profound metabolic changes, nota-
bly the downregulation of genes associated with normal liver functions
such as drug/xenobiotics metabolism and amino acid metabolism [11-
15]. Whether the altered metabolic state affects HCC response to ERK
pathway inhibitors is largely unaddressed. The poorly differentiated
HCC cell lines are potentially useful models for studying how metabo-
lism impacts therapeutic response. These cells largely retain human
liver tumour metabolic gene expression pattern [15], and exhibit a
dependency on extracellular glutamine (Gln)  a crucial amino acid in
intermediary metabolism [16-23]. Therefore, in this study, we deprived
HCC cells of extracellular Gln and examined the impact on metabolism,
the ERK signalling pathway, and sensitivity to kinase inhibitors. Our
findings show that severe alteration of HCC cell metabolism correlates
with ERK pathway activation, and suggest that inhibiting the ERK path-
way induces undesired consequences when metabolism is severely
compromised.
2. Material and methods
2.1. Cell culture
The HCC cell lines HEP3B, PLC/PRF/5, HUH1, HEPG2, HLE, HLF and
HUH7 were obtained from the Japanese Cancer Research Resources
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Dr. Kathrin Woll (University of Heidelberg, Germany); SNU398 was
from Dr. Francois Helle (University of Picardie Jules Verne, France),
while SNU449 was from Dr. Cedric Coulouarn (INSERM, France). All cells
were Mycoplasma-tested with PCR Mycoplasma Test Kit (PromoCell,
Germany). HLE, HUH7 and SNU398 cells were re-authenticated by Short
Tandem Repeat analysis. Liver cancer patient-derived cell lines (PDCLs)
were established from surgical specimen obtained at the University of
Mainz, Germany, following patient informed consent and local ethics
committee approval. Isolation and establishment of PDCLs were as
recently described [24]. The cell lines were cultured in DMEM (Lonza,
BE12-709) supplemented with 2mM glutamine, 10% foetal bovine
serum (FBS), penicillin (100 m/mL), streptomycin (100 mg/mL), and
were used within 10 passages after thawing. For glutamine withdrawal
experiments, the cells were washed 1x with Hank's Balanced Salt Solu-
tion (HBSS) or phosphate buffered saline (PBS) prior to experiments
with glutamine-free media. Serine deprivation experiment were per-
formed with culture media constituted with DMEM powder (D9802-1,
USBiological) according to the manufacturer’s instructions. The metabo-
lites used for supplementation experiments as well as drugs/inhibitors
used are listed in the Supplementary Table 3.
2.2. Proliferation and clonogenic assays
Cell proliferation was measured in quadruplicates using 3-(4,5-
dimethylthiazol-2-yl)2,5-diphenyltetrazolium bromide assay (MTT,
M5655-1 G, Sigma) in 96-well plates. Most experiments comparing
HUH7 and HLE cells were performed in parallel or on the same plate
with HUH7 cells in the upper aspect of the plate and HLE cells in the
lower aspect. Further details about the proliferation and clonogenic
assays are in the Supplementary file.
2.3. Western blotting and quantitative PCR
Western blot, RNA isolation and quantitative reverse transcription
PCR (RT-qPCR) were performed as recently described [15]. Antibodies
used for western blot are as follows: AKT (rabbit, # 9272), pAKT (rab-
bit, # 9271) from Cell Signalling Technology; PSAT1 (rabbit, # PA5-
22,124) from Thermofisher Scientific; and ERK (mouse, sc-135,900),
pERK (mouse, sc-7383), goat anti-mouse IgG-HRP (sc-2060), and goat
anti-rabbit IgG-HRP (sc-2301) from Santa Cruz Biotechnology. The
gene primers used for qPCR are listed in the Supplementary Table 4.
2.4. Metabolomics profiling
For intracellular metabolite profiling of Gln-deprived HUH7 and
HLE cells, the cells were seeded in triplicates in 12-well plates and
cultured for 24 h with DMEM containing 10% dialysed FBS, 25mM
glucose and 4mM Gln (Sigma-Aldrich). The same culture condition
was used for glucose-carbon isotope tracing except that for the trac-
ing experiment glucose-free DMEM was supplemented with 25mM
uniformly labelled glucose (U-13C-glucose) (Cambridge Isotope Labo-
ratories). The extraction of intracellular metabolites, quantification
by gas chromatography-mass spectrometry (GCMS) and mass isoto-
pologue distribution analysis were performed as previously
described [25]. For extracellular metabolite profiling in serum-free
media, HLE and HUH7 cells were seeded in 12-well plates in dupli-
cates. After overnight incubation, the culture media was changed to
serum-free media (with or without Gln) to minimise any confound-
ing effect of cell proliferation. 50ml of media sample was collected
from each of the duplicate wells at 0, 24, 28, 32, 48 h time points.
Samples from each time point were pooled and subsequently ana-
lysed by GCMS or liquid chromatography-mass spectrometry (LC-
MS/MS) as previously described [26]. The metabolomics results were
normalised to the corresponding cell count from parallel plate set-up. Further details on the metabolomics profiling of serine‑free or
-supplemented HLE cells are in the Supplementary file.2.5. Microarray analysis of glutamine deprived HLE cells
Gene expression analysis of HLE cells cultured in complete media,
Gln-free media and or in Gln-free media containing 20mM U0126
was performed using Affymetrix human HuGene-2_0-st-type arrays.
Biotinylated antisense cDNA was prepared according to the Affyme-
trix standard labelling protocol with the GeneChip WT Plus Reagent
Kit and the GeneChip Hybridization, Wash and Stain Kit (Affymetrix,
Santa Clara, USA). Afterwards, hybridisation on the chip was per-
formed on a GeneChip Hybridization oven 640, followed by dye in
the Fluidics Station 450 and scanning with GeneChip Scanner 3000.
Custom CDF version 22 with ENTREZ-based gene definitions was
used for array annotation [27]. Subsequently, the raw fluorescence
intensity values were normalised by applying quantile normalisation
and RMA background correction using SAS JMP10 Genomics package,
version 6 (SAS Institute, North Carolina, USA). Limma package was
used to identify differentially expressed genes. The microarray data-
set has been deposited in the NCBI GEO under the accession number
GSE123062.2.6. Human HCC microarrays datasets
Five human HCC microarray datasets GSE14323 (19 non-tumour vs
38 HCC tissues), GSE25097 (243 non-tumour vs 268 HCC tissues),
GSE14520 (220 non-tumour vs 225 HCC tissues), GSE39791 (72 non-
tumour vs 72 HCC tissues) and GSE57951 (39 non-tumour vs 39 HCC
tissues), altogether 593 non-tumour and 642 liver tumour samples,
were obtained from the National Centre for Biotechnology Information
Gene Expression Omnibus (NCBI GEO) and analysed as previously
described [14]. A list of 458 genes associated with the RAS/RAF/MAPK/
ERK pathway, including growth factors, were compiled from the KEGG
database (https://www.genome.jp/kegg/) and published literature
[3-5]. Using this list, the genes differentially expressed at P<0.05 in
tumour versus non-tumour samples were extracted from the HCC
datasets. Thereafter, the average log fold change of a differentially
expressed gene across the datasets was used to rank and determine
the upregulated or downregulated genes. Twenty four top upregulated
ERK genes were selected and used for tumour stratification analysis.2.7. HCC tumour stratification based on 24 ERK pathway gene
signatures
The expression values for the 24 genes were extracted for each
tumour sample in two HCC datasets  GSE14520 (n = 225 samples) and
GSE25097 (n = 268 samples). Using these values, the tumour samples
per dataset were ranked by their average expression of the ERK path-
way genes and this along with k-means clustering was used to separate
each dataset into highERK or lowERK group. After determining the
groups, limma package was used to determine the differentially
expressed genes in highERK versus lowERK HCC samples per dataset.
For survival analysis with metabolic genes, a previously reported consis-
tently altered metabolic gene list was used [14]. Upregulated metabolic
genes in HCC that were also upregulated in ERK-stratified tumours
were named ‘highUpMET’, whereas those that were low in highERK
tumours were named ‘lowUpMET’ and vice versa for the consistently
downregulated genes. Subsequently, KaplanMeier (KM) survival anal-
ysis was performed for tumours that have highERK and the metabolic
gene expression pattern indicated in the figures. The data analysis was
performed with R software (https://www.r-project.org/), while KM was
plotted in GraphPad Prism 8.
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Genes commonly high or low in highERK tumours from GSE14520
(P<0.05) and GSE25097 (P<0.01) were selected. The average z-score
of the genes across the two datasets was used to generate a ranked
list of differentially expressed genes in highERK relative to lowERK
HCC tumours. Using the ranked list, gene set enrichment analysis
was performed with the GSEAPreranked tool (software.broadinsti-
tute.org/GSEA, version 4.0.1).
2.9. Immunohistochemistry
Paraffin-embedded tissues from 15 HCC tumour samples were
stained for the expression of Ki67 - Dako (M7240) at 1:70 and pERK -
Cell Signalling Technology (9101) at 1:150 following established
immunohistochemistry (IHC) protocol. Microscopy images of 5 fields
per slide were taken with Zeiss Axio Scope.A1, and staining quantifi-
cation obtained with ZEN software (blue edition) v2.3.
2.10. Statistical analyses
Results are expressed as mean § standard deviation (SD) unless
stated otherwise. Graphical plots and statistical testing were per-
formed with GraphPad Prism 68 (La Jolla, CA, USA). T-test or ANOVA
was applied for group comparison where applicable. R software (ver-
sion 3.5.2) was used for analysing microarray datasets. In general, a
P-value less than 0.05 was considered statistically significant.
3. Results
3.1. Glutamine deprivation severely impairs metabolism and activates
ERK pathway in HCC cells
We previously showed that poorly differentiated HCC cell lines have
notable metabolic alterations. These cells express a low level of several
genes that encode amino acid pathway enzymes, and are highly depen-
dant on extracellular Gln for proliferation [15]. Here we confirmed their
high Gln dependency using an extended panel of 10 cell lines as well as
patient-derived primary liver cancer cells (PDLCs) (Fig. 1a, Supplemen-
tary Fig. 1a). To understand the link between metabolism and the ERK
pathway, we studied the effect of Gln deprivation mainly in a represen-
tative poorly-differentiated cell line HLE compared to HUH7 (a well-dif-
ferentiated cell). These two cells were selected because compared to the
others, they have been better characterised at metabolomics, proteomics
and signalling levels and found to be largely distinct representativemod-
els of HCC molecular features [15]. We found that Gln withdrawal cause
a sustained proliferation arrest in HLE cells (Fig. 1b). However, this sup-
pressed growth can be rescued by complete media even after 7 days,
indicating that the cells remained viable (Fig. 1b, Supplementary Fig. 1b).
Further, oxygen consumption was reduced and can also be rescued by
restoring complete media (Supplementary Fig. 1c). In contrast, prolifera-
tion arrest and reduced oxygen consumption were not observed in
HUH7 cells (Fig. 1b, Supplementary Fig. 1c). Freshly isolatedmouse hepa-
tocytes also did not display extracellular Gln dependency (Supplemen-
tary Fig. 1d), supporting that Gln dependency is a feature of malignantly
transformed cells.
To determine the metabolic changes that accompanied Gln-
deprived HLE compared to HUH7 cells, we analysed the cells’ intra-
cellular and extracellular metabolite profile following Gln depriva-
tion. In the intracellular compartment, pyruvate and lactate levels
were significantly reduced in HLE cells (Fig. 1c), suggesting a reduced
glycolytic activity. In addition, the intermediates of the TCA cycle (e.g.
aKG, malate) were depleted. Also depleted were the intermediates of
glutaminolysis/transamination (e.g. glutamate, aspartate, alanine) for
which Gln is a known biosynthetic substrate. These changes were far
less prominent in HUH7 (Fig. 1c), consistent with it being capable ofcompensatory de novo Gln synthesis as previously reported [28]. Of
note, the intracellular metabolite profile of HUH7 and HLE cells was
largely consistent with, and mirrored, that of the extracellular com-
partment as assessed under serum-free condition (Fig. 1d). Thus,
both intra- and extracellular metabolite profiling confirmed a pro-
found metabolic alteration in Gln-deprived HLE cells. Using isotope
tracing, we found that upon Gln deprivation, 13C-glucose labelling of
glutaminolysis intermediates (i.e. glutamine, glutamate, aKG) was
increased in both cell lines. However, consistent with defective
metabolism in HLE cells, its glucose-carbon labelling of Gln in the
absence of extracellular Gln was only »27% compared to »80% in
HUH7 cells (Fig. 1e). Glucose-carbon labelling pattern of glutamate
and aKG or malate and aspartate was similar in both cells
(»4648%) (Supplementary Fig. 2a), confirming that HLE cells were
uniquely inefficient at compensating for extracellular Gln depriva-
tion. Other alterations exclusive to HLE cells, such as increased
expression of glucose transporter SLC2A1 and a high expression of
the Warburg effect repressor mitochondrial pyruvate carrier (MPC1)
[29] (Supplementary Fig. 2b), supported that HLE cells have a
severely compromised glycolysis and other metabolic activities when
Gln-deprived.
We performed microarray analysis with the Gln-deprived HLE cells
and found a strong downregulation of multiple metabolic pathways
(Supplementary Fig. 2c), further confirming that Gln deprivation
severely perturbed HLE cell metabolism. These metabolic alterations
were accompanied by a strong induction of MAPK/ERK pathway genes
(Fig. 1f), including MAPK12/13, MAP2K2, and transcriptional regulators
MYC, ATF4, ELK1, DDIT3, MXD1 and NDRG1  most of which are often
associated with tumourigenic function and previously identified in
Gln-deprived HEP3B cells [30]. The MAPK/ERK genes were also similarly
expressed in Gln-deprived triple-negative breast cancer cell MDA-MB-
231 (Supplementary Fig. 3a), which is a known Gln-reliant cell line
[19,23]. Besides triggering the ERK pathway, the metabolic alterations
in HLE cells led to the induction of other signalling and inflammatory
networks, e.g. cytokine-to-receptor interaction, MTORC, tumour necro-
sis factor alpha and insulin signalling pathways (Fig. 1f, Supplementary
Figs. 2c and 6a). Using aminooxyacetate (a pan-transaminase inhibitor)
and asparaginase both of which disrupts Gln metabolism [17,22], we
validated the expression changes of selected metabolic targets (GLS,
FASN) and ERK pathway genes AREG, MYC, MXD1 and found a much
stronger response in HLE cells compared to HUH7 cells (Supplementary
Fig. 3b). At the protein level, Gln deprivation induced ERK phosphoryla-
tion (pERK) in HLE cells by 24 h and this persisted up to 7 days, whereas
pERK was induced in HUH7 cells at the later time point (Fig. 1gh).
There was no noticeable change in pERK in mouse hepatocytes (Fig. 1i,
48 h), which as mentioned earlier did not display Gln dependency. Alto-
gether, a severe metabolic impairment as resulted from Gln deprivation
in the poorly differentiated cells lead to ERK pathway induction.
3.2. High intracellular serine in the glutamine-deprived state partly
influences ERK pathway activity
Consistent with a prior report on HCC cells [31], the serine biosyn-
thesis pathway (SBP) genes, e.g. phosphoglycerate dehydrogenase
(PHGDH) and phosphoserine aminotransferase (PSAT1), were promi-
nently upregulated in Gln-deprived HLE cells (Fig. 2a) [31]. The
enzymes encoded by these genes mediate the initial steps in de novo
serine synthesis (Fig. 2b), which raised the possibility that the Gln-
deprived cells were actively synthesising serine. This notion, superfi-
cially, was supported by our metabolomics data that showed »2-fold
increase in intracellular serine, glycine, and methionine  all three of
which are connected via the SBP (Fig. 2b). Further, assessment of
independent human HCC tissue- and serum-based metabolomics
studies revealed that serine level is elevated in patients samples
(Supplementary Table 1), suggesting that serine accumulation has a
clinical relevance in HCC. However, in contrast to Gln-deprived cells,
Fig. 1. Severe metabolic alterations in HCC cells activate the ERK pathway. A. MTT proliferation assay of well-differentiated cells compared to poorly differentiated cell lines after
48 h of Gln deprivation. Box plot indicates mean § S.E.M. of the proliferation data of 5 well-differentiated (HUH7, HEPG2, HEP3B, PLC/PRF/5, HUH1) and 5 poorly differentiated cells
(SNU475, SNU398, SNU449, HLE, HLF) in glutamine (Gln)-free relative to complete media (CM). On the right, proliferation of patient-derived primary HCC cells, 72 h. B. Clonogenic
assay with or without Gln. Fresh complete media (CM) or glutamine free media (- Gln), was introduced on Day 1 and 7 as indicated. The cells were stained with crystal violet after
14 days culture. C. Intracellularmetabolite profile after 24 h culturewith orwithout Gln. Error bars indicate mean§ S.E.M of 3 experiments. Cy. Cycle. Pyr pyruvate, Lac lactate, Cit cit-
rate, aKG alpha ketoglutarate, Fum  fumarate, Mal malate, Ser serine, Met  methionine, Gly glycine, Glu glutamate, Asp aspartate, Ala alanine. D. Extracellular metabolite
profile showing the proportion of metabolites consumption or secretion by HUH7 and HLE cells after Gln deprivation in serum-free media. The bars indicate mean § S.E.M of the measured
amount at 24, 28, 32 and 48h after Gln deprivation relative to complete media, which is the baseline indicated with a broken line. Glc glucose, E. Schematic of 13C-glucose carbon labelling
pattern in HUH7 and HLE cells deprived of extracellular Gln as deduced from isotope tracing. Broken line indicates the removal of glutamine from culture media. " - increase, # - decrease.
Numbers in bracket indicate % of glucose-derived carbon that labelled the indicated metabolite in the respective cell line. m  the mass shift that contributed the most to the labelling. On
the right, 13C-glucose labelling of glutamine in HUH7 and HLE, respectively. F. Heatmap showing the expression pattern of 51 differentially regulated ERK pathway genes (P<0.05) in Gln-
deprived HLE cells. Underneath, MAPK pathway and other signalling-related pathway enrichment plots. G. Densitometric quantification of pERK level detected in western blots after gluta-
mine deprivation at 24 h and 48h (quantification from 4 experiments). H. Western blot showing pERK induction in HUH7 and HLE cells 7 days after culture in CM or Gln-free media. The
western blot run included pAKT (shown). I. Western blot and densitometric quantification of pERK in two mouse hepatocyte isolates (48h, 2 technical replicates). Error bars representmean
§ SD. Statistical significance: *P< 0.05, **P< 0.01, ***P< 0.001, ****P< 0.0001.
Z.C. Nwosu et al. / EBioMedicine 54 (2020) 102699 5most SBP genes are downregulated in HCC tumours [14]. Thus, we
wondered what the connections are between SBP gene induction,
high intracellular serine, proliferation arrest and high pERK as seen in
HLE cells.First, we considered that the SBP gene induction is largely indica-
tive of metabolic stress given that glucose deprivation [31] as well as
the withdrawal of several other essential amino acids, as observed in
published microarrays [32], also induces SBP genes. Thus, we tested
Fig. 2. High intracellular serine contributes to ERK phosphorylation. A. Volcano plot showing the topmost 20 differentially expressed metabolic genes in the microarray of Gln-
deprived HLE cells, 24 h. Genes having - log2FC are downregulated; +log2FC are upregulated. B. Schematic depiction of the serine biosynthesis pathway, including the interconnec-
tion between serine, glycine and methionine; on the right, intracellular metabolite data showing serine (SER), glycine (GLY) and methionine (MET) levels in Gln-deprived HUH7
and HLE cells. Error bars indicate mean § S.E.M, representative of 3 experiments. C. Crystal violet staining comparing the effect of 5mM serine, glycine and methionine on HLE cells,
72 h. Here the cells were seeded at a higher density prior to the metabolite supplementation. Representative of n>2 experiments. D. Clonogenic assay showing the selective effect
of serine load on HLE cells. Representative of n>2 experiments, 72 h. Cell number in  Gln condition was 2x CM condition. E. CellTitre Glo viability assay following serine deprivation
in a panel of HCC cell lines, after 48 h. The error bars indicate mean § SD, n = 4. F. Intracellular metabolic profiling showing the level of serine after 24 h culture in the indicated cul-
ture media conditions. The error bars indicate mean § SD, n = 3 samples. G. Intracellular metabolic profiling showing the level of glutamine after 24 h in the indicated culture media
conditions. The error bars indicate mean§ SD, n = 3 samples. H. Extracellular level of serine and glutamine as well as intracellular glutamine after 24 h in the indicated culture media
conditions. Error bars indicate mean§ SD, n = 3 samples. I. Western blot showing the effect of serine load on pERK levels compared to glycine and methionine, 24 h. Each of the three
metabolites were supplemented at 10mM concentration. J. Western blot densitometric plots of the effect of serine removal or supplementation on pERK levels in 5 HCC cell lines,
24 h. Representative of 2 technical repeat experiments. K. Clonogenic assay showing the protective effect of blocking the ERK pathway on HLE cells supplemented with serine in
Gln-deprived state. Cells were treated for 3 days in the indicated conditions, followed by culture in complete media for another 4 days. DMSO  dimethyl sulphoxide (drug solvent).
6 Z.C. Nwosu et al. / EBioMedicine 54 (2020) 102699the involvement of the NRF2-mediated oxidative stress pathway,
which has been shown to regulate SBP [33]. PSAT1 was the most
upregulated SBP component upon Gln deprivation (Fig. 2a) and cou-
ples Gln metabolism to SBP (Fig. 2b). However, although most NRF2genes were also upregulated in Gln-deprived HLE cells, the knock-
down of NRF2 (NFE2L2) did not affect PSAT1 (Supplementary Fig. 3c).
Moreover, stratification of human HCC tumours by ERK signatures
(discussed later) showed that PHGDH, PSAT1, and notable NRF2-
Z.C. Nwosu et al. / EBioMedicine 54 (2020) 102699 7pathway genes (i.e. NFE2L2, KEAP1, HMOX1, SOD2) are not high in
‘high-ERK’ expressing tumours (Supplementary Table 2). We there-
fore considered the metabolite-level difference i.e. high intracellular
serine to be more relevant to ERK signalling, given its consistency
with the ERK pathway activation in vitro and in human HCC.
No prior study has reported that serine, glycine or methionine accu-
mulate under a compromised metabolism. To delineate the implication
of such accumulation, we cultured Gln-starved HUH7 and HLE cells
with high serine, glycine and methionine (each at 5mM; equivalent to
12.525x normal culture media level). Of the three amino acids, only
serine supplementation caused the detachment of the Gln-deprived
HLE cells (Fig. 2c). This detrimental effect was evident in HLE cells cul-
tured with »1mM (2.5x basal culture media serine) in HLE (Fig. 2d),
and in other Gln-reliant cells HEPG2 and HLF cells (Supplementary Fig.
4a), but was not observed in the non-extracellular Gln-reliant cells
HUH7 (Fig. 2cd, Supplementary Fig. 4b) or mouse hepatocytes even at
the extremely high serine concentrations (1020mM, »50x normal)
(Supplementary Fig. 4c). Serine supplementation in complete media
barely suppressed proliferation, albeit having more effect on HLE cells at
higher concentration (Supplementary Fig. 4d). Removing serine from
media did not affect viability or proliferation of multiple HCC cell lines
(Fig. 2e, Supplementary Fig. 4e), together indicating that exogenous ser-
ine is dispensable for the HCC cells. Thus, we concluded that a high ser-
ine load impedes proliferation only when metabolism is severely
impaired.
We next wanted to determine the source of the accumulating ser-
ine. As previously reported in breast cancer [34], a possible source of
serine is glycolysis through the PHGDH-mediated diversion of 3-
phosphoglycerate to serine synthesis (Fig. 2b). However, in both
HUH7 and HLE cell lines, isotope tracing experiment showed that
13C-glucose-derived carbon in serine was reduced when Gln is with-
drawn (Supplementary Fig. 5a). Since this finding excluded glycolysis
as the source of serine in Gln-deprived HLE cells, we considered the
extracellular compartment (i.e. culture media) as another possible
source. Interestingly, extracellular metabolite profiling of serum-free
media (shown in Fig. 1d) revealed that overall serine consumption
was increased in Gln-deprived HUH7 but reduced in HLE cells. We
interpreted this data as implying that HLE cells in a severely compro-
mised metabolic state retain the ability to take up serine but lack the
capacity to efficiently metabolise it  hence the accumulation. Con-
sistent with this notion, HLE cells had »2-fold higher intracellular
serine when cultured in Gln-deprived condition compared to com-
plete media when each was supplemented with 1mM serine (Fig. 2f).
On the other hand, intracellular serine was attenuated when serine
was withdrawn from culture media (Fig. 2f), supporting that the
accumulated serine is from the extracellular compartment.
Serine supplementation marginally reduced intracellular Gln lev-
els, thus partially mimicking Gln deprivation (Fig. 2g). However,
although serine withdrawal suppressed Gln consumption (Fig. 2h),
most other glutaminolysis metabolites that were depleted by Gln
deprivation (e.g. glutamate, aspartate and malate) were either ele-
vated or not strongly impacted by serine supplementation or with-
drawal (Supplementary Fig. 5be). Therefore, we concluded that
high intracellular serine is a consequence and not the cause of the
severely altered metabolic state, and only partially mimicked Gln
withdrawal at the metabolite level.
We then tested whether high serine is linked to the ERK pathway
induction. Interestingly, supplementation with serine, but not methi-
onine or glycine, contributed to high pERK in Gln-deprived HLE cells
(Fig. 2i), further supporting the selective effect of high serine load.
Serine induction of pERK1/2 was further confirmed by ELISA-based
phosphoprotein array (Supplementary Fig. 5f), and by immunoblot-
ting in HLF and PLC cell lines, but was not evident in another highly
Gln-reliant cell line SNU398 indicating cell-autonomous differences
(Fig. 2j, Supplementary Fig. 5 g). Since high pERK increases therapeu-
tic resistance in liver cancer [35,36], we tested whether high serineload impacts HCC cell response to ERK inhibition. We found that
when Gln-deprived serine‑supplemented HLE cells are co-treated
with MEK inhibitors (Fig. 2k), multi-kinase inhibitor Sorafenib and
epidermal growth factor receptor inhibitor Erlotinib, the cells became
protected from the detachment observed with serine supplementa-
tion alone (Supplementary Fig. 5 h). These data provide novel evi-
dence that serine accumulates in a severely impaired metabolic state
and contributes to ERK pathway activation as well as kinase inhibitor
resistance.
3.3. Blocking the ERK pathway in a severely impaired metabolic state
initiates proliferation as a resistance phenotype
Elevated ERK signaling has been observed in various cancer types
making it an ideal pathway to target. However, for yet unknown rea-
sons, such intervention also lead to drug resistance [3,5]. Given our
observation of high pERK in the background of metabolic alterations
and proliferation arrest, we hypothesised that when metabolism is
severely compromised, blocking the accompanying pERK could facili-
tate proliferation as a resistance phenotype. Indeed, a prior study
showed that Gln-deprived pluripotent stem cells are more prolifer-
ative when cultured with inhibitors of MAPK and GSK3b [37], thus
supporting the notion that kinase inhibitors can drive proliferation.
In complete media, Sorafenib, Erlotinib, and MEK/pERK inhibitor
(U0126) suppressed the proliferation of HUH7 and HLE cells (Fig. 3a).
These inhibitors were less potent in HLE cells (Fig. 3a), which express
higher pERK and MAPK genes at basal level [15]. The inhibitors were
effective at decreasing pERK level regardless of Gln availability
(Fig. 3b). Despite decreasing pERK, the inhibitors had anti-prolifer-
ative effect on Gln-deprived HUH7 cells whereas Gln-deprived HLE
cells were insensitive to the treatments (Fig. 3c). HLE 'resistance' to
pERK inhibition was also evident when U0126 was combined with
Asparaginase (Fig. 3c)  an enzyme that mimics Gln deprivation
[15,17]. Further, Gln-deprived HLE cells were more proliferative in
complete media when pre-treated with pERK inhibitors (U0126,
SCH772984, Trametinib and PD0325901) (Fig. 3d). Microarray analy-
sis of the effect of U0126 in Gln-deprived HLE cells confirmed that
the inhibitor acts directly on the MAPK/ERK pathway. In addition,
U0126 suppressed several signalling and inflammatory components
induced by Gln deprivation alone (Fig. 3e, Supplementary Fig. 6ab).
These results reveal that while targeting the MAPK/ERK pathway
may be anti-proliferative in unperturbed cellular state, it could
enhance proliferation when metabolism is severely compromised.
Consistent with the above, treatment with 10058-F4 (an inhibitor of
MYC) and the knockdown of the max dimerisation complex 1
(MXD1), both of which are downstream of the ERK pathway, also
increased the proliferative capacity of Gln-deprived HLE cells (Sup-
plementary Fig. 7ab). Indeed, an increased pERK did not indicate an
increased cell proliferation in the impaired metabolic state. We fur-
ther confirmed this by stimulating Gln-deprived cells with epidermal
growth factor (EGF), which increased pERK level as expected but did
not induce HLE cell proliferation (Fig. 3f).
Combination of kinase inhibitors is a clinically tried strategy for
overcoming cancer drug resistance. However, contrary to our expec-
tation, the poorly differentiated HCC cell lines are more resistant to
the combination of U0126 with Erlotinib and even the well-differen-
tiated cells varied in their response (Fig. 3g, Supplementary Fig. 7c).
Noteworthy, while the HCC cells were broadly stratified into well
and poorly differentiated subclasses, their mRNA expression of
MAP2K1 (MEK1), MAP2K2 (MEK2), MAPK3 (ERK1) and MAPK1
(ERK2) suggest they cluster into at least 4 subsets (Fig. 3h). Resistance
to U0126 and Erlotinib combination was most obvious in Gln-
deprived HLE and HLF cells, and these two cell lines proliferated
more and looked morphologically healthier upon prolonged treat-
ment with the inhibitor combination (Fig. 3i, Supplementary Fig. 7d).
When compared to HUH7 cells, Erlotinib combination with the
Fig. 3. Blocking the ERK pathway in an impaired metabolic state enables proliferation. A. MTT proliferation assay following treatment of HUH7 and HLE cells with Sorafenib (multi-
kinase inhibitor) Erlotinib (EGFR inhibitor), and MEK/pERK inhibitor U0126, in complete medium, 48 h. The asterisks indicate significant p-value compared to the untreated group.
B. Western blot analysis of HUH7 and HLE cells treated with the indicated inhibitors, 24 h. C. Proliferation assay, showing the effect of Sorafenib, Erlotinib and U0126 in Gln-deprived
media, 48 h. On the right, effect of U0126 in media containing Asparaginase. Asterisks indicate significant p-value compared to the untreated group (UT), which refers to cells cul-
tured in  Gln or in Asparaginase media without U0126. D. Clonogenic assay showing the response of Gln-deprived HUH7 and HLE cells to the indicated MEK inhibitors. The inhibi-
tor concentrations are as follows: U0126 (10 mM), SCH772984 (0.25 mM), Trametinib (0.5 mM). Cells were treated for 4 days, followed by rescue with complete media for 3 days. E.
Pathway annotation of 569 genes that were upregulated in Gln-deprived HLE, but suppressed by U0126 treatment [20mM]. The annotation profile was generated with DAVID
(https://david.ncifcrf.gov/tools.jsp). The embedded Venn diagram shows the total number of differentially expressed genes at P<0.05. F. Proliferation assay showing the effect of epi-
dermal growth factor (EGF) stimulation, 48 h. The embedded western blots show pERK induction following EGF stimulation, 24 h. G. Proliferation assay showing the effects of Erloti-
nib, U0126 or a combination of both on the HCC cell lines. H. Heatmap of RT-qPCR results showing the relative mRNA expression of the indicated MAPK/ERK genes in HCC cell lines.
Blue  low, Red  high, each gene is scaled relative to the lowest expressing cell line. I. Schematic of ERK pathway inhibition by Erlotinib and U0126, and proliferative effect on the
resistant cell lines HLE and HLF. On the right, representative microscopic image showing the appearance of Gln-deprived HLE and HLF cells treated for 15 days with Erlotinib and
U0126 combination. Where applicable, statistical significance is *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. UT  untreated or drug solvent DMSO where treatment was
applied; Number per group = 4 for proliferation assays and plotted relative to UT for either CM or  Gln.
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HLE cells (Supplementary Fig. 7e). The kinase inhibitors strongly
induced pAKT in both HUH7 and HLE cells (Fig. 3b), which raised the
possibility that a compensatory AKT signaling enabled the cellsurvival in the Gln-deprived state. We ruled out this possibility
because treatment with phosphoinositide-3-kinase inhibitor
LY294002 itself facilitated cell proliferation, especially when com-
bined with U0126 (Supplementary Fig. 7f). These results show that
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cells, high pERK may not indicate higher cell proliferation, and that
blocking the ERK pathway can lead to increased cell proliferation.3.4. Blocking the ERK pathway induces profound metabolic
reprogramming that drives resistance
Inhibition of the MAPK pathway following Sorafenib treatment of
ex vivo HCC tissue was accompanied by altered expression of meta-
bolic pathway enzymes, notably in glycolysis [47]. In line, our micro-
arrays showed that metabolic pathways, alongside MAPK pathway,
are the most strongly perturbed in Gln-deprived U0126-treated HLE
cells (Fig. 3e). The metabolite changes induced by kinase inhibitors
are largely unaddressed in HCC.
We sought to determine the spectrum of metabolite-level changes
that accompany MAPK/ERK pathway inhibition, mainly with respect
to HLE cells where resistance to the kinase inhibitors occurred upon
Gln deprivation. Measurement of glycolytic activity via glucose
uptake and lactate secretion showed that U0126 alone (Supplemen-
tary Fig. 8a) or in combination with Erlotinib or more potently Sorafe-
nib (Fig. 4a), induced an increase in glycolysis. Consistent with
glycolysis being crucial for the kinase-inhibitor resistance, treatment
with glycolysis inhibitor 2-deoxy-glucose (2DG) suppressed the
residual proliferative activity of Gln-deprived HLE cells (Fig. 4b), and
synergised with the combination of Sorafenib and U0126 in eight
tested HCC cell lines (Fig. 4bc). Of note, HUH7 and HLE cells are nor-
mally sensitive to 2DG in complete media [15]. Thus, the effect
observed with 2DG confirmed that the kinase inhibitors acted via a
different mechanism that enable, rather than suppress, metabolic
programs that promote cell proliferation.
We compared the intracellular metabolite profile of HUH7 and
HLE cells that were treated with U0126 in complete media (i.e.where
U0126 suppressed proliferation in both cells) or in Gln-deprived
media (i.e. where HLE cells were insensitive to the anti-proliferative
effect of U0126). In complete media, U0126 suppressed most TCA
cycle intermediates in both cell lines (Supplementary Fig. 8b). Inter-
mediates of transamination reaction, i.e. pyruvate, alanine and aspar-
tate, were also suppressed. U0126 had no tangible effect on the
intracellular pool of serine, methionine, glycine, glutamine and gluta-
mate, which were among metabolites earlier identified to be changed
by Gln deprivation (Figs. 1 and 2). Noteworthy, U0126 suppressed
13C-glucose-carbon enrichment of serine (Supplementary Fig. 8c),
consistent with preventing the diversion of glycolysis intermediates
into the SBP pathway. Altogether, under optimal growth conditions,
blocking the ERK pathway specifically suppressed the TCA cycle
intermediates and downstream components of transamination.
In the Gln-deprived condition, where HLE cell metabolism is
severely compromised, U0126 increased the intracellular levels of
malate and other TCA cycle intermediates. In addition, components
of transamination/glutaminolysis such as glutamine, glutamate,
aspartate and alanine were increased (Fig. 4d). Isotope tracing further
showed that 13C-glucose-carbon enrichment of notably malate and
aspartate is elevated in U0126-treated HLE cells (Fig. 4e). Consistent
with a physiologic link between the increase in these metabolites
and the ERK inhibitor resistance, culture media supplementation
with glutamate, a-ketoglutarate and malate had a rescue effect on
the proliferation arrest in Gln-deprived HLE cells (Supplementary Fig.
8d). ERK inhibition suppressed transamination genes (Supplementary
Fig. 8e), and reversed metabolic pathway alterations induced by Gln
deprivation (Fig. 4f). These data support our proposed model (Fig. 4g)
that ERK inhibition enhances cell proliferative capacity when metab-
olism is severely compromised in a poorly differentiated HCC cell, by
inducing glycolysis, the TCA cycle, and other metabolic adaptations.3.5. Upregulated ERK pathway gene signatures indicate liver tumour
metabolic alterations in patients
Our in vitro studies showed a strong link between an upregulated
ERK pathway and a compromised metabolism. We wanted to know
whether such correlation exist in patients. Noteworthy, studies have
shown that human HCC tissues often express high pERK, and display
profound metabolic alterations at gene, protein and metabolite levels
[11,14,38]. To determine if an upregulated ERK pathway correlates
with human HCC tumour metabolic alterations, we analysed the
expression pattern of »450 ERK pathway genes in five microarray
datasets (consisting of 642 HCC tumour tissue samples in total). We
found that the ERK pathway genes are not uniformly upregulated in
HCC. Specifically, while most MAPK genes are upregulated (Fig. 5a),
growth factors, especially EGF ligands and fibroblast growth factors
are either low or not consistently expressed across the cohorts (Sup-
plementary Fig. 9a). We identified 24 ERK gene signatures that have
a combined high expression across the five HCC datasets.
Using those 24 ERK gene signatures (Supplementary Fig. 9b), we
defined “highERK” and “lowERK” HCC tumours in the two largest
datasets in our analysis (Fig. 5b)  each of which contains over 200
tissue samples. In the highERK tumours, the topmost downregulated
genes were predominantly metabolic genes (Fig. 5c) and included
many poorly understood genes in HCC such as HPD (in tyrosine catab-
olism), SDS (in serine catabolism), CYP4A11 (in xenobiotic metabo-
lism), FBP1, PCK1 (in gluconeogenesis) and ALDOB (in fructose
metabolism). Similarly, several metabolic genes were high in high-
ERK tumours, including HK2, ALDOA, ENO1 (in glycolysis), TKT (in
pentose phosphate pathway), ASNS (in asparagine metabolism), and
ACSL4, SCD, LPCAT1, SQLE and FADS1 in cholesterol/lipid metabolism,
together suggesting that a high expression of the ERK pathway signa-
tures indicate an altered metabolic profile in human HCC.
While the genes commonly upregulated in highERK clusters from
both datasets had high MAPK pathway enrichment as expected,
genes commonly downregulated in those tumours were strongly
involved in metabolic processes (Fig. 5d), including fatty acid, xenobi-
otics and amino acid pathways known to be altered in liver and other
cancers [39]. Thus, a high ERK pathway signature specifically predicts
a severe metabolic alteration in HCC (Fig. 5e), especially for those bio-
chemical pathways involved in physiological liver function. Besides
metabolism, we assessed evidence of proliferation in our ERK-strati-
fied datasets given our observation of proliferation arrest along with
high pERK in vitro. Using a list of known proliferation markers
(including TOP2A, MKI67, PCNA, RRM2, MCM2  6, CCNB1, CCND1
and CCNE1), we found that most of the proliferation genes were
highly expressed in highERK tumours (Fig. 5f), suggesting no overlap
with the in vitro data with respect to these markers. Nevertheless,
immunohistochemical analysis of the proliferation marker Ki67 and
pERK in 15 HCC samples yielded variable results between samples,
with some samples showing very low pERK staining (Fig. 5g). These
data are consistent with a duality in ERK signalling in patients, and
suggest a stronger overlap between ERK and metabolism.
We wondered whether highERK genes have a relevant correlation
with prognostic outcomes in HCC patients. Using 87 genes that were
recently published as predictors of a poor response to Sorafenib [36],
we found that »40% were high in highERK tumours at least in one of
the two stratified datasets (Supplementary Fig. 9c). Lastly, we ana-
lysed patient survival outcome based on the 24 ERK gene signatures
and their accompanying consistently altered metabolic genes in HCC
as previously reported [14]. HighERK signatures correlated with poor
survival outcome (Fig. 5h). HighERK correlation with poor survival
was stronger when the tumours were further stratified using consis-
tently upregulated metabolic genes (Fig. 5i) or downregulated meta-
bolic genes in human HCC tissues (Fig. 5j). Taken together, these data
establish a strong link between ERK signalling activation and a dysre-
gulated metabolism in human HCC tumours.
Fig. 4. Blocking the ERK pathway reprograms metabolism. A. Glucose consumption and lactate output after treatment of HUH7 cells (48 h) and HLE cells (24 h) with the indicated
inhibitors in the Gln-free media, n = 3 per group. B. MTT proliferation assay, 48 h after treatment with glycolysis inhibitor 2-deoxy-glucose, and Sorafenib (2.5 mM)+ U0126 (20 mM)
combination; n = 4 per group. C. CellTitre Glo viability assay, 48 h after treatment with glycolysis inhibitor 2-deoxy-glucose, and Sorafenib (2.5 mM), U0126 (20 mM) combination;
n = 4 per group. D. Intracellular metabolite profiling showing the effect of U0126 (20 mM) in Gln-deprived state. Bars indicate mean § S.E.M. of two experiments. Pyr  pyruvate,
Lac  lactate, Cit  citrate, aKG  alpha ketoglutarate, Fum  fumarate, Mal  malate, Ser  serine, Met  methionine, Gly  glycine, Glu  glutamate, Asp  aspartate, Ala  ala-
nine, Cy  cycle, Glutamin.  glutaminolysis. E. Mass isotopologue distribution of 13C-glucose carbon in malate and aspartate in Gln-deprived HUH7 and HLE cells treated with
U0126 (20 mM). Bars indicate mean § S.D, n = 3 per group. F. GSEA plots showing metabolic pathways suppressed by Gln deprivation and induced upon the treatment of Gln-
deprived HLE cells with U0126. G. Summary of the consequences of inhibiting the ERK pathway in an unperturbed metabolic state of the well-differentiated cell line versus in a
severely compromised metabolic state of the poorly differentiated HCC cell.
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We provide a new evidence that poorly differentiated HCC cells
activate the ERK pathway when metabolism is severely compromised,
and propose that this interaction could explain why liver cancer resistkinase inhibitors [7]. We find that at least in two cell lines, phenotypic
response to ERK pathway inhibition is governed by metabolic state. To
study the link between metabolism and ERK signalling, we took the
approach of depriving HCC cells of glutamine. Depriving rapidly prolif-
erating cells of Gln causes a plethora of highly reproducible changes,
Fig. 5. High ERK gene signatures indicate alteredmetabolism in patients tumours. A. Heatmap showing the expression ofMAPK genes in 5 human liver cancermicroarray datasets. Blue -
low expression, red  high expression, white  not significant. Cut-off for significant expression per dataset is P<0.05. B. The topmost 24-ERK gene signatures identified from the 5 HCC
microarray datasets and used to stratify tumours into highERK and lowERK group in the dataset GSE14520 (n = 225 samples) and GSE25097 (n = 268 samples). C. Topmost differentially
expressed metabolic genes in highERK tumours. Upper panel shows previously defined consistently upregulated genes in HCC that are also high in highERK tumours, while lower panel
shows consistently downregulated genes in HCC that are also low in highERK tumours. D. GSEA plot showing the upregulation of MAPK pathway and downregulation of metabolic pro-
cesses in highERK tumours. Plots were generated using 2607 genes, amongst which 1776 are commonly upregulated in highERK tumours from GSE14520 and GSE25097, whereas 831
are commonly downregulated in highERK tumours in both datasets. E. Schematic representation of a reciprocal balance between ERK pathway activation and metabolic status of HCC. F.
Expression profile of proliferation markers in HCC tumours expressing high ERK signatures. Values indicate z-score per dataset. Negative values indicate a downregulation; - indicate not
available or statistically significant. G. Representative immunohistochemical stain of Ki67 (proliferation marker encoded by MKI67 gene) and pERK in three patients tissue samples. On
the right, a quantification of percentage positive cells from 5 fields per sample from 15 patients. H. KaplanMeier overall survival analysis of HCC tissue samples stratified based on the
24-ERK gene signatures. I. KaplanMeier overall survival analysis of HCC tissue samples stratified based on the 24-ERK gene signatures and the consistently upregulatedmetabolic genes
in HCC. ‘UpMET’ or ‘DownMET’ refers to whether themetabolic genes are those consistently upregulated or downregulated, respectively, in HCC. J. KaplanMeier overall survival analysis
of HCC tissue samples stratified based on the 24-ERK gene signatures and the consistently downregulatedmetabolic genes in HCC. The KaplanMeier plots were generated with the clin-
ical data from GSE14520. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
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of transporters/metabolic genes (e.g. SLC7A11, MPC1, HK2, PC, PSAT1,
GLS), activation of the NRF2-stress pathway, induction of transcription
factors (MYC, MXD1, ATF3/4, DDIT3), and suppression of proliferation
[18-22,33,37,40-43]. Several of these molecular changes exist in
human tumours when compared to adjacent normal tissues. In addi-
tion, they broadly indicate altered cancer metabolism, and have moti-
vated the quest to target Gln metabolism in the clinic [16]. As shown
in our study, some of these changes occur in a well-differentiated cell
line that can proliferate without extracellular Gln, albeit to a lesser
degree. By comparing a typically extracellular Gln-reliant to a well-dif-
ferentiated cell, we have unravelled extensive and severe metabolic
perturbations that occur mainly in the poorly differentiated cells. We
report that under such metabolic impairments, ERK pathway inhibi-
tion can accelerate glycolysis and channel glucose-derived carbon
towards glutaminolysis intermediates.
Of the metabolic consequences that accompanied Gln deprivation,
we were curious about changes in the serine biosynthesis pathway
(SBP). The exact function of the SBP is unclear in HCC as well as other
cancer types. For example, the SBP was previously identified as a major
driver of oncogenesis in breast and colon cancer [34,44,45]. However,
in lung cancer the SBP components were found to be heterogeneously
expressed and not always functional [33]. In HCC tumours and the
poorly differentiated cell lines, most SBP genes are expressed at a low
level [14,15]. Upon nutrient starvation, e.g. glucose or glutamine depri-
vation, c-MYC can regulate the SBP in HCC cells [31]. These findings
suggest that SBP may be critical or redundant depending on the cell
contexts. At least in the context of cell proliferation, c-MYC regulation
of SBP seems physiologically counterintuitive since in the Gln-deprived
cells MYC is upregulated alongside the SBP genes, whereas prolifera-
tion is arrested. Further evidence indicating that the withdrawal of
other amino acids or glucose also induces SBP [31,32], suggest that the
upregulation of SBP genes following Gln deprivation does not truly
reflect serine metabolic activity. Based on our data, we propose that
SBP gene induction is highly consistent with proliferation arrest, defec-
tive metabolism, and inability to specifically metabolise serine. Consis-
tently, while serine, methionine and glycine accumulate in the absence
of Gln, the Gln-reliant HCC cells detach from monolayer only when
supplemented with high serine but neither methionine nor glycine. To
our knowledge, this is the first evidence showing that poorly differen-
tiated HCC cells need Gln to promote serine metabolism, proliferation,
and to maintain a low intracellular serine level. Our experiments in
serine‑free media provided no compelling evidence of extracellular
serine dependency across HCC cell lines. Thus, high intracellular serine
as observed in human liver cancer tissues [38] and in non-alcoholic
fatty liver disease [46], could be a novel clinically important indicator
of severe metabolic impairment. We showed that the high intracellular
serine contributed to ERK pathway activation and primed the poorly
differentiated cells to kinase inhibitor resistance. Further studies will
be required to better understand the clinical role of serine in HCC and
the specific portals through which it is internalised.
Another crucial finding of broad clinical implication is the strong
correlation between ERK pathway and dysregulated metabolic path-
ways in vitro and in human HCC tissues. Indeed, despite elevated
pERK in HCC tumour samples, the reasons for kinase inhibitor resis-
tance is vaguely understood [7]. One possible explanation is that the
inhibitors act on unintended targets. For example, the antiprolifera-
tive effect of tivantinib as tested in >30 HCC cell lines was reported
to be due to its anti-mitotic effect and not due to the expected MET
signalling inhibition [51]. Even when acting on the intended targets,
a plethora of tumour promoting alterations may occur via currently
unknown compensatory mechanisms. Our data suggest that there
might be conditions, at least altered cancer metabolism, under which
high pERK may not reflect a suppressed cell proliferation. Under such
conditions, there might be little or no justification for targeting ERK
pathway by itself. Instead, given that tumours resistant to Sorafenibshow profound induction of MAPK components and pERK [35,47,48],
it is quite probable that high pERK predicts a severely impaired meta-
bolic state and the likelihood of resistance. Consistent with this view,
we show that targeting the ERK pathway in the Gln-deprived state
induces proliferation and unintended metabolic reprogramming (e.g.
aerobic glycolysis), which are unfavourable outcomes if occurring in
patients. Similar observations have been made in prior studies. For
example, Dazert and colleagues observed "a strong enrichment of
pathways involved in central carbon metabolism" in a biopsied Sora-
fenib-treated liver tumour that resisted therapy [47]. In addition,
metabolic reprogramming as a driver of resistance has been observed
upon NOTCH1 inhibition in T cell acute lymphoblastic leukaemia
[49], and with BRAF V600E inhibitor Vemurafenib in melanoma [50].
Thus, our work can facilitate new discoveries on the drivers and pre-
dictors of drug resistance in HCC. We also presented 24 consistently
upregulated components of the MAPK pathway that predicted the
altered metabolic gene profile of HCC patients tumours. Accordingly,
we propose the inclusion of metabolic profiling and ERK signatures
in the algorithms to stratify HCC patients for kinase inhibitor therapy.
In conclusion, we have found that a severely impaired metabo-
lism can drive ERK pathway activation in a subset of HCC cells.
Blocking pERK when metabolism is altered leads to metabolic
reprograming and increases the proliferation of such cell lines.
While this work is limited by a lack of in vivo evidence in experi-
mental models, our analyses of human tumour collectives reveal a
solid correlation between high expression of ERK pathway genes
and dysregulated metabolic gene networks in HCC tissues. We
believe our findings apply more to HCC tumours of poorly differenti-
ated grade, but that tumour heterogeneity may limit the actual sub-
sets even further. We therefore propose that the combination of
signatures of impaired metabolism and ERK signalling activation
could be an ideal precision medicine strategy to predict HCC
patients best suited for kinase inhibitor therapy.
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